TRAIL responses are enhanced by nuclear export inhibition in osteosarcoma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Tumour necrosis factor-related apoptosis inducing ligand (TRAIL) shows anti-cancer potential by inducing apoptosis.
• TRAIL resistance and TRAIL-insensitive disease limit the efficacy of TRAIL-based therapies.
• TRAIL-sensitizers are needed to enhance TRAIL activity and overcome resistance.

Purpose of the Study:

• To investigate the potential of Leptomycin B as a TRAIL-sensitizer in osteosarcoma.
• To evaluate the synergistic effects of Leptomycin B with TRAIL and death receptor agonists.
• To determine if Leptomycin B overcomes TRAIL resistance in osteosarcoma cell lines.

Main Methods:

• In vitro studies using osteosarcoma cell lines.
• Treatment with Leptomycin B, TRAIL, and death receptor 5 agonistic antibodies.
• Assessment of apoptosis induction and TRAIL sensitivity/resistance.
• Evaluation of aldehyde dehydrogenase (ALDH) positive cell response.

Main Results:

• Leptomycin B acts as a potent in vitro TRAIL-sensitizer in osteosarcoma cells.
• Leptomycin B synergizes with TRAIL and death receptor 5 agonistic antibodies to induce apoptosis.
• Leptomycin B sensitizes TRAIL-insensitive osteosarcoma cells to apoptosis.
• ALDH-positive cells are not resistant to Leptomycin B and TRAIL-induced apoptosis.

Conclusions:

• Leptomycin B is a promising TRAIL-sensitizer for osteosarcoma treatment.
• Combining nuclear export inhibition with death receptor agonists is a potential therapeutic strategy.
• Further research into selective nuclear export inhibitors is warranted for osteosarcoma therapy.